Shares tumble 3% as Sun Pharma's Dilip Shanghvi ends 2020 shareholder agreement
Shares tumble 3% as Sun Pharma's Dilip Shanghvi ends 2020 shareholder agreement
Investor group's director resigns; Shanghvi's statement assures continued investment in Suzlon
Shanghvi and associates held 7.4% stake; emphasize commitment to wind energy's potential
February 2020 saw approval of debt restructuring and issuance of equity shares to raise funds
Sun Pharma's 2015 stake acquisition, followed by Suzlon's recent positive performance
Growing interest in sustainable energy boosts Suzlon; stock delivers over 145% returns in the past year